USE OF BOTULINUM TOXIN TYPE A IN MANAGEMENT OF ADULT SPASTICITY - A EUROPEAN CONSENSUS STATEMENT
Anthony B. Ward A1, Miguel Aguilar A2, Zegers De Beyl A3, Susanne Gedin A4, Petr Kanovsky A5, Franco Molteni A6, Jörg Wissel A7, Anton Yakovleff A8
A1 Department of Rehabilitation Medicine, North Staffordshire Hospital, Stoke-on Trent, UK.
A2 Department of Neurology, Hospital Mutua Terrassa, Barcelona, Spain.
A3 Department of Neurology, Hôpital Erasme, Université Libre de, Bruxelles, Belgium.
A4 Department of Neurology, Helsingborg Hospital, Sweden.
A5 Department of Neurology, Masaryk University, Brno, Czech Republic.
A6 Movement Disorders Rehabilitation Unit, Valduce Rehabilitation Centre, Costa Masnaga, Lecco, Italy.
A7 Department of Neurology, Clinic for Neurorehabilitation, Beelitz-Heilstatten, Germany.
A8 Clinical Neurology, Université de Paris V-René Descartes, France
This article does not have an abstract.
Do you want to comment on this paper? The comments will show up here and if appropriate the comments will also separately be forwarded to the authors.
You need to login/create an account to comment on articles. Click here to login/create an account